Home  >  Research  >  Labs  >  Cancer Program  >  LIVER DISEASE AND CARCINOGENESIS

RESEARCH OVERVIEW

Our research group focuses on the liver progenitor/stem cell (LPSC) which we identify in patients with alcoholic liver disease (ALD), hepatitis C (HCV), genetic hemochromatosis (GH) and non-alcoholic fatty liver disease (NAFLD). An objective of our research is to utilise their presence as a diagnostic to detect early stages of pathology and their abundance as an indicator of disease severity. Since ALD, GH, HCV and NAFLD increase the likelihood of developing hepatocellular carcinoma (HCC), the LPSCs may also be useful as a prognostic for patients who will develop liver cancer.

We are well-placed to undertake these studies as we have a monoclonal antibody that detects the LPSCs in liver biopsies. Our recent studies suggest that the protein this antibody binds to is present in the blood of patients who harbour LPSCs in their liver. This raises the possibility of developing a blood test that informs clinicians of the state of the patient’s liver.

The LPSC is present in diseased liver because it has an important role in repairing the damaged organ. It is a functional stem cell that can produce cholangiocytes that make up the bile ducts; or it can produce hepatocytes that are responsible for the major functions of the liver. To better study this important liver cell, we have established LPSC lines from both the mouse and human to understand what makes them grow and how they decide between generating cholangiocytes and hepatocytes.

This work has produced a valuable resource in the form of LPSC lines that are non-cancerous and others that are tumorigenic. This provides a platform for screening and testing for anti-liver cancer drugs that are selectively effective against liver cancer cells.

 

Emeritus Professor George Yeoh

Emeritus Professor George Yeoh

Liver Disease and Carcinogenesis

Read more

LATEST NEWS

Perkins researchers put paid to plaque in arteries

The Harry Perkins Institute of Medical Research is celebrating a major milestone in the progression of a world-first drug candidate that has the potential to change the lives of thousands of Australians with atherosclerosis, a disease which can cause the build-up of cholesterol and other lipids (fats) in the walls…

Read More

New research: Slowing the spread of brain cancer

A new study involving researchers from the Harry Perkins Institute of Medical Research has uncovered a potential way to slow the growth and spread of one of the deadliest forms of brain cancer - glioblastoma.  Glioblastoma is an aggressive, fast-growing tumour that often resists standard treatments like chemotherapy and radiation.  …

Read More

Perkins partners with Victor Chang Cardiac Research Institute for better heart outcomes

The Harry Perkins Institute of Medical Research has forged a new partnership with one of Australia’s leaders in heart research. The strategic partnership with the Victor Chang Cardiac Research Institute (VCCRI) in Melbourne reinforces the Perkins commitment to tackling heart disease across the nation. Professor Girish Dwivedi, Group Leader of…

Read More

I'M LOOKING FOR

RESEARCH PROJECTS

TEAM MEMBERS

PUBLICATIONS